Skip to main navigation
  • Home
  • Synthetic Biology
    • The History of Synthetic Biology
  • Living Medicines
    • Designing Synthetic Bioticâ„¢ Medicines
  • Pipeline + Programs
    • Partner with Us
  • For Patients
  • Our People
    • Leadership
    • Board of Directors
    • Founders and Advisors
    • Join Us
  • Investors + Media
    • Company Overview
    • News & Events
      • News Releases
      • Events
      • In the News
    • Presentations & Publications
    • Stock Information
    • Corporate Governance
    • Financials
    • Investor Resources
explore the
possibilities

Synlogic Therapeutics

Investor Relations

SEC Filing Details

  • Home
  • Synthetic Biology
    • The History of Synthetic Biology
  • Living Medicines
    • Designing Synthetic Bioticâ„¢ Medicines
  • Pipeline + Programs
    • Partner with Us
  • For Patients
  • Our People
    • Leadership
    • Board of Directors
    • Founders and Advisors
    • Join Us
  • Investors + Media
    • Company Overview
    • News & Events
      • News Releases
      • Events
      • In the News
    • Presentations & Publications
    • Stock Information
    • Corporate Governance
    • Financials
    • Investor Resources

SEC Filing Details

Document Details

Form
4
Filing Date
May 25, 2022
Document Date
May 24, 2022
Form Description
Statement of changes in beneficial ownership of securities
Filing Group
3,4,5
Company
Synlogic
Issuer
SYNLOGIC, INC.
Filer
JENSEN MICHAEL VANGSTED

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS
  • Email Alerts
  • Contact IR
  • RSS Feeds
  • Print Page
  • Email Page

Synlogic Therapeutics

Contact

Synlogic

301 Binney St #402
Cambridge, MA 02142

info@synlogictx.com
(617) 401-9975

  • Twitter
  • LinkedIn

Privacy and Terms

© 2022 Synlogic
Privacy Policy